Iris Cheung and Noel Courage’s Article Published in The Lawyer’s Daily

September 20, 2022

Article “Canadian regulators wade into Alzheimer’s drug controversy” by Iris Cheung and Noel Courage was published in The Lawyer’s Daily.

“In June 2022, neuroscience firm Biogen withdrew its Canadian drug submission for approval of aducanumab, which is a monoclonal antibody drug for the treatment of Alzheimer’s disease (AD).”

Click here to read the full article published by The Lawyer’s Daily (, part of LexisNexis Canada Inc., in September 2022.

Subscribe to our newsletter

You can unsubscribe at any time. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

This site is registered on as a development site.